In a post‑NSTEMI patient without contraindications, should I initiate a β‑blocker, an ACE inhibitor, and a mineralocorticoid receptor antagonist (MRA)?

Post-NSTEMI Medical Therapy: β-Blockers, ACE Inhibitors, and MRAs

Yes, initiate all three medication classes in your post-NSTEMI patient without contraindications, with specific indications determining the strength of recommendation for each agent.

β-Blocker Therapy

Initiate oral β-blocker therapy within the first 24 hours unless the patient has signs of heart failure, evidence of low-output state, increased risk for cardiogenic shock, or other contraindications (PR interval >0.24 seconds, second/third-degree heart block, active asthma/reactive airway disease) 1, 2, 3.

Key Implementation Points:

• Class I recommendation (Level of Evidence: A-B) across all major guidelines 1, 2, 3, 4
• Risk factors for cardiogenic shock to screen for: age >70 years, systolic BP <120 mmHg, sinus tachycardia >110 or heart rate <60, prolonged time since symptom onset 1, 5
• Re-evaluate patients with initial contraindications after 24 hours for subsequent eligibility 2
• For patients with stabilized heart failure and reduced systolic function, use sustained-release metoprolol succinate, carvedilol, or bisoprolol 2

Evidence Nuance:

Recent data suggest the mortality benefit of β-blockers may be attenuated in the contemporary reperfusion era for patients with preserved ejection fraction, particularly beyond 1 year post-MI 6. However, guideline recommendations remain unchanged, and acute initiation (within 24 hours) continues to show benefit in most patient subgroups 7. The 2025 ACC/AHA guidelines acknowledge ongoing study in this area but maintain the Class I recommendation 4.

ACE Inhibitor Therapy

ACE inhibitor indications are stratified by risk:

Class I (Must Initiate):

Administer orally within the first 24 hours to patients with 1, 3, 4:

• Pulmonary congestion OR
• LVEF ≤40%
• Absence of hypotension (SBP <100 mmHg or >30 mmHg below baseline)
• No contraindications

Class I (High-Risk Features):

Continue indefinitely in patients with 8, 3, 4:

• LVEF ≤40%
• Hypertension
• Diabetes mellitus
• STEMI with anterior location

Class IIa (Reasonable for All):

It is reasonable to prescribe ACE inhibitors to all post-NSTEMI patients without high-risk features (Level of Evidence: A-B) 8, 1, 4. The 2025 guidelines support this broader application 4.

ARB Alternative:

Use ARB if ACE inhibitor intolerant with clinical/radiological signs of heart failure or LVEF ≤40% 1, 3.

Supporting Evidence:

Long-term ACE inhibitor/ARB therapy reduces 4-year all-cause mortality in NSTEMI patients treated with PCI (HR 0.75, ARR 4.0%) 9. Optimal blood pressure control (SBP ≤130 mmHg) with ACE inhibitors/ARBs is associated with reduced long-term adverse events 10.

Mineralocorticoid Receptor Antagonist (MRA) Therapy

Initiate MRA therapy if the patient meets ALL of the following criteria 8, 3, 4:

Class I Indications:

1. LVEF ≤40% AND
2. Either symptomatic heart failure OR diabetes mellitus AND
3. Already receiving therapeutic doses of ACE inhibitor AND
4. Adequate renal function:
   • Estimated creatinine clearance >30 mL/min
   • Serum potassium ≤5.0 mEq/L

Evidence Base:

• Class I recommendation (Level of Evidence: A-B) based on EPHESUS trial demonstrating mortality reduction 8, 3, 4
• Recent 2025 meta-analysis confirms MRA reduces composite cardiovascular endpoints (RR 0.89), cardiovascular mortality, heart failure events, and all-cause mortality (RR 0.88) in ACS patients 11
• MRAs improve left ventricular remodeling (increased LVEF, reduced LVESV/LVEDV) 11

Critical Safety Monitoring:

• Hyperkalemia risk increased 2.14-fold 11
• Monitor potassium and renal function closely
• Acute eGFR decline of ~2 mL/min/1.73 m² expected in first 4-6 months, but no long-term kidney disease progression 12

Real-World Utilization Gap:

Despite Class I recommendations, only 25-28% of eligible post-MI patients receive MRAs 13, 14. Do not be part of this underutilization trend—actively assess eligibility and prescribe when indicated.

Clinical Algorithm Summary

For your post-NSTEMI patient without contraindications:

1. β-blocker: Initiate within 24 hours (Class I) unless contraindications present
2. ACE inhibitor:
   • Mandatory if LVEF ≤40%, pulmonary congestion, hypertension, or diabetes (Class I)
   • Reasonable for all others (Class IIa)
3. MRA: Add if LVEF ≤40% + (HF symptoms OR diabetes) + adequate renal function/potassium (Class I)

Target parameters at discharge: SBP ≤130 mmHg and pulse rate ≤80 bpm for optimal outcomes 10.